Wendy A Keitel

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi request reprint A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization
    W A Keitel
    Departments of Microbiology, Immunology, and Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    J Infect Dis 180:397-403. 1999
  2. pmc Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial
    Wendy A Keitel
    Baylor College of Medicine, Houston, TX 77030, USA
    J Infect Dis 198:1309-16. 2008
  3. doi request reprint Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants
    Wendy A Keitel
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Infect Dis 198:1016-8. 2008
  4. ncbi request reprint Preparing for a possible pandemic: influenza A/H5N1 vaccine development
    Wendy A Keitel
    Baylor College of Medicine, Room 221D, One Baylor Plaza, BCM 280, Houston, TX 77030, United States
    Curr Opin Pharmacol 7:484-90. 2007
  5. ncbi request reprint Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine
    Wendy A Keitel
    Baylor College of Medicine, Molecular Virology and Microbiology and Medicine, Room 221 D One Baylor Plaza, Houston, TX 77030, USA
    Expert Rev Vaccines 5:417-30. 2006
  6. ncbi request reprint Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons
    Wendy A Keitel
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Tex 77030, USA
    Arch Intern Med 166:1121-7. 2006
  7. ncbi request reprint Cellular and acellular pertussis vaccines in adults
    W A Keitel
    Department of Microbiology, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Infect Dis 28:S118-23. 1999
  8. ncbi request reprint Repeated immunization of children with inactivated and live attenuated influenza virus vaccines: safety, immunogenicity, and protective efficacy
    Wendy A Keitel
    Department of Molecular Virology and Microbiology, Rm 221D, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Semin Pediatr Infect Dis 13:112-9. 2002
  9. ncbi request reprint Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid
    W A Keitel
    Department of Microbiology and Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Vaccine 18:531-9. 1999
  10. ncbi request reprint Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults
    W A Keitel
    Departments of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA
    J Infect Dis 183:329-332. 2001

Collaborators

Detail Information

Publications33

  1. ncbi request reprint A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization
    W A Keitel
    Departments of Microbiology, Immunology, and Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    J Infect Dis 180:397-403. 1999
    ..Antibody levels fell significantly during the year after immunization. These data support evaluation of ACVs for broader use among adolescents and adults...
  2. pmc Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial
    Wendy A Keitel
    Baylor College of Medicine, Houston, TX 77030, USA
    J Infect Dis 198:1309-16. 2008
    ..Dose-sparing strategies are being explored for vaccines against pandemic influenza. We evaluated the dose-sparing potential of aluminum hydroxide (AlOH) adjuvant...
  3. doi request reprint Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants
    Wendy A Keitel
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Infect Dis 198:1016-8. 2008
    ..Increasing the influenza vaccine dosage safely and predictably enhanced antibody responses to the vaccine virus and to subsequent, antigenically different, influenza A/H1N1 variants...
  4. ncbi request reprint Preparing for a possible pandemic: influenza A/H5N1 vaccine development
    Wendy A Keitel
    Baylor College of Medicine, Room 221D, One Baylor Plaza, BCM 280, Houston, TX 77030, United States
    Curr Opin Pharmacol 7:484-90. 2007
    ..Whether or not a pandemic spread of the A/H5N1 virus occurs, lessons learned as a result of these activities will better prepare us for future pandemics, as well as for interpandemic influenza...
  5. ncbi request reprint Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine
    Wendy A Keitel
    Baylor College of Medicine, Molecular Virology and Microbiology and Medicine, Room 221 D One Baylor Plaza, Houston, TX 77030, USA
    Expert Rev Vaccines 5:417-30. 2006
    ..Future licensure of these and other candidate vaccines will depend on their safety and immunogenicity profiles in humans, and their ability to confer protection in animal models of inhalational anthrax...
  6. ncbi request reprint Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons
    Wendy A Keitel
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Tex 77030, USA
    Arch Intern Med 166:1121-7. 2006
    ..Immune responses after influenza immunization are reduced in elderly individuals, the group at greatest risk for complications and death after influenza. Improved vaccines are needed to address this problem...
  7. ncbi request reprint Cellular and acellular pertussis vaccines in adults
    W A Keitel
    Department of Microbiology, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Infect Dis 28:S118-23. 1999
    ..A clear understanding of the impact of pertussis in adolescents and adults will help to define the need for booster immunization after childhood...
  8. ncbi request reprint Repeated immunization of children with inactivated and live attenuated influenza virus vaccines: safety, immunogenicity, and protective efficacy
    Wendy A Keitel
    Department of Molecular Virology and Microbiology, Rm 221D, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Semin Pediatr Infect Dis 13:112-9. 2002
    ..Additional data regarding the effects of annual immunization are needed, and continued efforts to develop improved vaccines for the prevention of influenza are indicated...
  9. ncbi request reprint Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid
    W A Keitel
    Department of Microbiology and Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Vaccine 18:531-9. 1999
    ..Both MSP-1(19) vaccines were immunogenic in humans, but changes in formulation will be necessary to improve safety and immunogenicity profiles...
  10. ncbi request reprint Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults
    W A Keitel
    Departments of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA
    J Infect Dis 183:329-332. 2001
    ..Combined inl and im immunization is a promising approach for enhancing both local and systemic immune responses against influenza...
  11. pmc Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine
    Robert L Atmar
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Vaccine 29:8066-72. 2011
    ..Persons born before 1968 were not more likely to respond to a G9 H9N2 influenza vaccine than persons born in 1970 or later...
  12. pmc Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults
    Wendy A Keitel
    Baylor College of Medicine Vaccine Research Center, Houston, TX 77030, USA
    Vaccine 27:6642-8. 2009
    ..Because influenza antibody titers vary significantly between different laboratories, international standardization of assays is warranted...
  13. pmc A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults
    Robert L Atmar
    Department of Medicine, Baylor College of Medicine, Houston, TX 77030, United States
    Vaccine 25:5367-73. 2007
    ..Nasal IgA antibody responses were more common when vaccine was administered IN; and, when the IN dosage was increased, the primary benefit from IN vaccine over IM vaccine appeared to be greater induction of nasal secretory antibody...
  14. pmc Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans
    Robert B Couch
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, One Baylor Plaza, MS BCM 280, Houston, TX, USA
    Vaccine 27:5344-8. 2009
    ..Thus, despite exhibiting a significant adjuvant effect in mice, interferon did not exhibit an adjuvant effect for induction of antibody in respiratory secretions of humans to inactivated influenza virus vaccine given intranasally...
  15. pmc A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route
    Shital M Patel
    Baylor College of Medicine, Medicine Infectious Diseases, BCM MS 280, One Baylor Plaza, Houston, TX 77030, United States
    Vaccine 28:3025-9. 2010
    ..Higher dosages of H5 HA and/or inclusion of adjuvant will be required to enhance immunogenicity by the ID route...
  16. pmc Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines
    Robert B Couch
    Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Vaccine 31:190-5. 2012
    ..Recently we have shown that NA inhibiting antibody can independently contribute to immunity to naturally-occurring influenza immunity in the presence of antibody to the HA...
  17. pmc Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults
    Wendy A Keitel
    Baylor College of Medicine, Houston, TX, USA
    Hum Vaccin 5:536-44. 2009
    ..Despite the absence of TNA, 75% animals survived the lethal challenge. In summary, VCL-AB01 was generally well tolerated in humans at a dose that provided immunity in monkeys despite the lack of robust TNA titers in either species...
  18. pmc Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes
    Shital M Patel
    Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    J Infect Dis 206:1069-77. 2012
    ..Direct comparisons of similar doses of a novel influenza virus antigen administered by the intradermal route and the intramuscular route have not been reported...
  19. ncbi request reprint Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations
    Robert L Atmar
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Clin Infect Dis 43:1135-42. 2006
    ..Influenza A/H9N2 viruses can infect humans and are considered to be a pandemic threat. Effective vaccines are needed for these and other avian influenza viruses...
  20. doi request reprint Intanza(®): a new intradermal vaccine for seasonal influenza
    Robert L Atmar
    Department of Medicine, Baylor College of Medicine, 1 Baylor Plaza, MS BCM280, Houston, TX 77030, USA
    Expert Rev Vaccines 9:1399-409. 2010
    ..Intanza has more frequent injection-site reactions than intramuscularly delivered vaccine, but it is safe and well tolerated. Intanza provides a new option for the prevention of influenza...
  21. doi request reprint Clinical data on Fluarix: an inactivated split seasonal influenza vaccine
    Hana M El Sahly
    Department of Molecular Virology and Microbiology, One Baylor Plaza, BCM MS280, Houston, TX 77030, USA
    Expert Rev Vaccines 7:713-9. 2008
    ..However, vaccines with improved immunogenicity in at-risk populations, such as the elderly, and with less reliance on growth in eggs, as well as the inherent demanding timelines, are needed to enhance the control of influenza...
  22. doi request reprint Adjuvants for pandemic influenza vaccines
    Robert L Atmar
    Department of Medicine, Baylor College of Medicine 280, One Baylor Plaza, Houston, TX 77030, USA
    Curr Top Microbiol Immunol 333:323-44. 2009
    ..A number of other adjuvants are under investigation to evaluate their ability to improve the immunogenicity of inactivated vaccines targeting influenza A/H5N1...
  23. doi request reprint Pandemic H5N1 influenza vaccine development: an update
    Hana M El Sahly
    Department of Molecular Virology and Microbiology, One Baylor Plaza, BCM MS280, Houston, TX 77030, USA
    Expert Rev Vaccines 7:241-7. 2008
    ..There is a suggestion that prepandemic priming against drifted H5N1 variants is possible; however, additional data are needed. Newer approaches using live-attenuated, DNA vaccines and conserved epitopes are currently under development...
  24. pmc Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial
    Hana M El Sahly
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA
    J Infect Dis 205:703-12. 2012
    ..The immunogenicity of a high hemagglutinin (HA) dose or a second dose of influenza vaccine in human immunodeficiency virus (HIV)-infected individuals has not been fully explored...
  25. doi request reprint Vaccines for pandemic influenza: summary of recent clinical trials
    Wendy A Keitel
    Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, 280 One Baylor Plaza, Houston, TX 77030, USA
    Curr Top Microbiol Immunol 333:431-51. 2009
    ..The results of these and future trials will help to identify formulations and immunization regimens for various populations, and will better prepare us to address the threat of both pandemic and interpandemic influenza...
  26. doi request reprint Prenatal passive transfer of maternal immunity in Asian elephants (Elephas maximus)
    Sally A Nofs
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA
    Vet Immunol Immunopathol 153:308-11. 2013
    ....
  27. pmc Rapid research response to the 2009 A(H1N1)pdm09 influenza pandemic (Revised)
    Wendy A Keitel
    Department of Molecular Virology and Microbiology, Houston, TX, USA
    BMC Res Notes 6:177. 2013
    ..Sera were tested for the presence and level of HAI and neutralizing antibodies against the A(H1N1)pdm09 virus...
  28. doi request reprint Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old
    W A Keitel
    Baylor College of Medicine, Houston, TX 77030, United States
    Vaccine 28:379-85. 2009
    ..ILI frequencies were low and similar in both groups. Studies assessing relative immunogenicity of vaccines using identical B Ags are warranted...
  29. pmc Effects of infection and disease with Mycobacterium tuberculosis on serum antibody to glucan and arabinomannan: two surface polysaccharides of this pathogen
    Wendy A Keitel
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA
    BMC Infect Dis 13:276. 2013
    ..The role of the surface capsular polysaccharides (CPs) of Mycobacterium tuberculosis (Mtb) in the pathogenesis of infection and disease, as well their potential for use as diagnostic reagents and vaccine antigens, are unknown...
  30. pmc Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans
    H M El Sahly
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States
    Vaccine 27:4905-11. 2009
    ....
  31. ncbi request reprint Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination
    Upma Gulati
    Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, 940 Stanton Young Blvd, BMSB 840, Oklahoma City, OK 73104, USA
    Vaccine 23:1414-25. 2005
    ..Our assay, which has also been adapted for recent influenza viruses that do not bind to fetuin, may be useful for vaccine evaluation...
  32. ncbi request reprint Rapid licensure of a new, inactivated influenza vaccine in the United States
    John J Treanor
    University of Rochester, Rochester, New York 14642, USA
    Hum Vaccin 1:239-44. 2005
    ..We evaluated a split virus TIV (Fluarix, GSK), to generate data supportive of a license application in the US...
  33. pmc Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria
    Edwin A M Lee
    Molecular Immunology Group, Nuffield Department of Medicine, Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, United Kingdom
    Infect Immun 70:1417-21. 2002
    ..These data suggest that epitope-specific naturally acquired MSP-1(19) immune responses in endemic populations can be boosted by vaccination...